Propanc Biopharma reports pilot study shows anti-tumor efficacy for PRP proenzyme formulation in pancreatic, ovarian cancer
PPCB•Propanc Biopharma said a peer-reviewed pilot study found its PRP proenzyme therapy slowed tumor growth and reduced spread-related behavior in pancreatic and ovarian cancer models, with tolerable safety. Separate UK Specials use indicated longer-than-expected survival for a subset of advanced cancer patients, with no severe treatment-related events reported.
1. Pilot study findings
Propanc Biopharma reported results from a peer-reviewed pilot study published in Scientific Reports. Preclinical tests showed PRP slowed tumor growth and reduced spread-related behavior in pancreatic and ovarian cancer models, with tolerable safety; separate UK Specials use in advanced cancers indicated longer-than-expected survival for a subset of patients, with no severe treatment-related events reported.
